Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

XOMA Royalty Corporation - Common Stock (NQ:XOMA)

24.00 +0.85 (+3.67%)
Streaming Delayed Price Updated: 10:34 AM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about XOMA Royalty Corporation - Common Stock

< Previous 1 2 3 4 Next >
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
From XOMA Royalty Corporation
Via GlobeNewswire
The Analyst Verdict: XOMA Royalty In The Eyes Of 4 Experts
Via Benzinga
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
Forecasting The Future: 5 Analyst Projections For XOMA Royalty
Via Benzinga
A Glimpse Into The Expert Outlook On XOMA Royalty Through 4 Analysts
Via Benzinga
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty to Present at Investor Conferences in March
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
From XOMA Royalty Corporation
Via GlobeNewswire
Demystifying XOMA: Insights From 5 Analyst Reviews
Via Benzinga
Peeling Back The Layers: Exploring XOMA Through Analyst Insights
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For XOMA
Via Benzinga
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
From XOMA Corporation
Via GlobeNewswire
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
From XOMA Corporation
Via GlobeNewswire
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
From XOMA Corporation
Via GlobeNewswire
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
From XOMA Corporation
Via GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
XOMA Royalty to Present at Upcoming Investor Conferences in September
From XOMA Corporation
Via GlobeNewswire
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
From XOMA Corporation
Via GlobeNewswire
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
FDA's Genetic Metabolic Diseases Advisory Committee will review Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C on August 2. PDUFA decision expected by September 21. 
Via Benzinga
Exposures Product Safety
XOMA Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
From XOMA Corporation
Via GlobeNewswire
3 Crazy Good Stocks to Buy With $500 Right Now
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth. 
Via InvestorPlace
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
From XOMA Corporation
Via GlobeNewswire
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
From XOMA Corporation
Via GlobeNewswire
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
From XOMA Corporation
Via GlobeNewswire
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
From XOMA Corporation
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.